MULTISPECIFIC BINDING AGENTS AND USES THEREOF
Granted: January 11, 2024
Application Number:
20240010751
The present disclosure provides multispecific binding agents (e.g., antibodies, such as bispecific antibodies) that have a first binding domain that binds to CD47, including human CD47, and one or more additional binding domains that bind to one or more targets that are not CD47, such as PD-L1 and uses thereof.
MULTISPECIFIC BINDING AGENTS AND USES THEREOF
Granted: January 11, 2024
Application Number:
20240010751
The present disclosure provides multispecific binding agents (e.g., antibodies, such as bispecific antibodies) that have a first binding domain that binds to CD47, including human CD47, and one or more additional binding domains that bind to one or more targets that are not CD47, such as PD-L1 and uses thereof.
CD47 BINDING AGENTS AND USES THEREOF
Granted: November 9, 2023
Application Number:
20230357391
The present disclosure provides CD47 binding agents (e.g., antibodies, including multispecific antibodies, such as bispecific antibodies) and uses thereof.
PD-L1 BINDING AGENTS AND USES THEREOF
Granted: September 28, 2023
Application Number:
20230303699
The present disclosure provides PD-L1 binding agents (e.g., antibodies, including multispecific antibodies, such as bispecific antibodies) and uses thereof.
ANTI-ROR ANTIBODY CONSTRUCTS
Granted: May 27, 2021
Application Number:
20210155692
Anti-ROR antibody constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.
Triple Negative Breast Cancer Treatment Method
Granted: February 4, 2021
Application Number:
20210030737
Disclosed is a method of treating triple negative breast cancer in a human patient, comprising administering to the patient an amount of cabozantinib or a pharmaceutically acceptable salt thereof, wherein the amount of cabozantinib is sufficient to activate the immune system.
Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture
Granted: August 10, 2017
Application Number:
20170226131
The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof as well as methods of making and using the compounds.
Drug Combination to Treat Melanoma
Granted: August 10, 2017
Application Number:
20170224670
This invention relates to the combination of vemurafenib and the heat shock protein 90 (HSP90) inhibitor XL888 to treat melanoma, particularly BRAF V600 mutant melanoma in patients in need of such treatment.
Crystalline Solid Forms of N--N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, Processes for Making, and Methods of Use
Granted: February 16, 2017
Application Number:
20170044106
The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly…
LXR MODULATORS
Granted: October 20, 2016
Application Number:
20160304499
The present invention provides compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as modulators of liver X receptors (LXR), compositions comprising any of such novel compounds, methods of using these compounds or compositions as medicaments for prevention or treatment of diseases or disorders related to liver X receptor (LXR), as well as methods of preparing these LXR modulators and using them in the manufacture of medicaments.
LXR MODULATORS
Granted: October 6, 2016
Application Number:
20160289222
The present invention provides compounds of Formula I and Formula II: or pharmaceutically acceptable salts or solvates thereof, as modulators of liver X receptors (LXRs), and compositions comprising any of such novel compounds and methods of use thereof. These compounds are useful as medicaments for treatment and/or prophylaxis for diseases or conditions related to activity of LXRs.
LXR MODULATORS
Granted: September 29, 2016
Application Number:
20160280661
Compounds, pharmaceutically acceptable salts, isomers, or prodrugs thereof, of the invention are disclosed, which are useful as modulators of the activity of liver X receptors (LXR). Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
Cabozantinib Dosage Form and Use in the Treatment of Cancer
Granted: January 28, 2016
Application Number:
20160022662
This invention relates to a dosage form of cabozantinib and a method of employing the dosage form to treat cancer.
LXR MODULATORS
Granted: October 22, 2015
Application Number:
20150299136
Compounds, pharmaceutically acceptable salts, isomers, or prodrugs thereof, of the invention are disclosed, which are useful as modulators of the activity of liver X receptors (LXR). Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture
Granted: December 25, 2014
Application Number:
20140378436
The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies
Granted: October 9, 2014
Application Number:
20140303172
Methods are provided for treating a lymphoproliferative malignancy to a patient in need of such treatment, comprising administering to the patient an effective amount of compound A as described herein.
Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture
Granted: October 9, 2014
Application Number:
20140303151
The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab
Granted: October 9, 2014
Application Number:
20140302012
The invention provides a method for treating cancers including hematologic malignancies comprising administering a compound of Formula (I): in combination with one or both of bendamustine and rituximab.
Method of Treating Lymphoma Using Pyridopyrimidinone Inhibitors of PI3K/mTOR
Granted: October 2, 2014
Application Number:
20140296265
The invention provides a method for treating cancers including hematologic malignancies comprising administering a compound of formula I:
Combinations of Kinase Inhibitors for the Treatment of Cancer
Granted: September 18, 2014
Application Number:
20140271665
The present invention provides methods of treating cancer by administering a compound of formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with an inhibitor that targets HER2 and/or HER3.
